Metraipolis › archive › dc_41b44dc7daba

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors — Europe PMC PMID:41296842

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41296842
DOI: 10.1158/2767-9764.crc-25-0566
License (as archived): solo-consultazione
Archived: 2026-11-08T01:42:31.146Z
SHA-256 of the archived text: 4cf4cb9b9dfd39bfbf3e983fd428e4518b1a50077f08675196342469ec63ee8f
Stable URL of this page: https://metraipolis.com/documento/dc_41b44dc7daba

How to cite

Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors — Europe PMC PMID:41296842 — Europe PMC (en), https://europepmc.org/article/MED/41296842 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_41b44dc7daba (Metraipolis archive dc_41b44dc7daba, sha256 4cf4cb9b9dfd39bfbf3e983fd428e4518b1a50077f08675196342469ec63ee8f)

BibTeX

@misc{dc41b44dc7daba,
  title = {Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid Tumors — Europe PMC PMID:41296842},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41296842},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_41b44dc7daba; sha256 4cf4cb9b9dfd39bfbf3e983fd428e4518b1a50077f08675196342469ec63ee8f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41296842. Agents can read the archived copy with the MCP tool read_document.